Payment overview · 2025
General Payments
$530.77
27 reported records · 17 companies
Healthcare provider profile · identity verified
Daniel James Johnson, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRADENTON, FL · NPI 1740206549
Verified facts
What the public records show
CMS Open Payments records show Daniel James Johnson, MD received $530.77 in general payments during 2025 across 27 reported records.
ABBVIE INC. accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $133.84 | 25.2% | 6 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $50.39 | 9.5% | 3 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $48.76 | 9.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $39.67 | 7.5% | 2 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $33.89 | 6.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.91 | 5.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.00 | 4.5% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $22.16 | 4.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.83 | 4.1% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $21.73 | 4.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.52 | 3.3% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $16.68 | 3.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.82 | 2.8% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $14.71 | 2.8% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$14.17 | 2.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.91 | 2.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.78 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $530.77 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $71.24 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.60 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $55.90 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $50.39 | 3 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $48.76 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $39.67 | 2 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $33.89 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $31.60 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.69 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
96 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 810 | 224 |
| Levothyroxine Sodium | Levothyroxine Sodium | 540 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 449 | 132 |
| Lisinopril | Lisinopril | 426 | 123 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 421 | 129 |
| Losartan Potassium | Losartan Potassium | 405 | 119 |
| Alprazolam | Alprazolam | 402 | 84 |
| Omeprazole | Omeprazole | 345 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 336 | 99 |
| Simvastatin | Simvastatin | 272 | 77 |
| Zolpidem Tartrate | Zolpidem Tartrate | 261 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 249 | 74 |
| Gabapentin | Gabapentin | 242 | 68 |
| Metformin Hcl | Metformin Hcl | 228 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 227 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 207 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 62 |
| Sertraline Hcl | Sertraline Hcl | 202 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 183 | 44 |
| Trazodone Hcl | Trazodone Hcl | 180 | 50 |
| Meloxicam | Meloxicam | 159 | 52 |
| Allopurinol | Allopurinol | 157 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 154 | 40 |
| Furosemide | Furosemide | 151 | 59 |
| Prednisone | Prednisone | 149 | 89 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 36 |
| Lorazepam | Lorazepam | 139 | 29 |
| Tramadol Hcl | Tramadol Hcl | 134 | 36 |
| Eliquis | Apixaban | 126 | 28 |
| Famotidine | Famotidine | 119 | 39 |
| Montelukast Sodium | Montelukast Sodium | 115 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 30 |
| Azithromycin | Azithromycin | 106 | 73 |
| Finasteride | Finasteride | 104 | 30 |
| Ozempic | Semaglutide | 103 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 27 |
| Metformin Hcl Er | Metformin Hcl | 97 | 32 |
| Synthroid | Levothyroxine Sodium | 96 | 25 |
| Potassium Chloride | Potassium Chloride | 94 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 92 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 91 | 62 |
| Valsartan | Valsartan | 91 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 23 |
| Atenolol | Atenolol | 88 | 26 |
| Amoxicillin | Amoxicillin | 83 | 63 |
| Spironolactone | Spironolactone | 81 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 26 |
| Donepezil Hcl | Donepezil Hcl | 77 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 61 |
| Diazepam | Diazepam | 75 | 13 |
| Temazepam | Temazepam | 75 | 15 |
| Bupropion Xl | Bupropion Hcl | 74 | 23 |
| Methylprednisolone | Methylprednisolone | 74 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 27 |
| Cephalexin | Cephalexin | 72 | 49 |
| Oxycodone Hcl | Oxycodone Hcl | 72 | suppressed |
| Glimepiride | Glimepiride | 68 | 21 |
| Mirtazapine | Mirtazapine | 65 | suppressed |
| Xarelto | Rivaroxaban | 64 | 18 |
| Carvedilol | Carvedilol | 61 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 14 |
| Glipizide | Glipizide | 57 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 16 |
| Propranolol Hcl | Propranolol Hcl | 56 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 23 |
| Clonazepam | Clonazepam | 51 | 17 |
| Ezetimibe | Ezetimibe | 51 | 14 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | 12 |
| Celecoxib | Celecoxib | 47 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Fluconazole | Fluconazole | 43 | 21 |
| Ibuprofen | Ibuprofen | 43 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | suppressed |
| Lovastatin | Lovastatin | 41 | 12 |
| Valacyclovir | Valacyclovir Hcl | 41 | 20 |
| Jardiance | Empagliflozin | 40 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Estradiol | Estradiol | 39 | 11 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 24 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 26 |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 14 |
| Cefuroxime | Cefuroxime Axetil | 26 | 23 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 12 |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | 13 |
| Acyclovir | Acyclovir | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | 11 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Zoloft | Sertraline Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $530.77 · 27 records | ABBVIE INC. | CREON, Hizentra, INGREZZA, ISTURISA, Kerendia, Korlym, LINZESS, Leqembi, MOUNJARO, QULIPTA, Radicava, Senza, TEPEZZA, UBRELVY, VALTOCO, VIBERZI, VOQUEZNA, VOWST, WAINUA, ZENPEP, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error